MedPath

OTOVEL

These highlights do not include all the information needed to use OTOVEL safely and effectively. See full prescribing information for OTOVEL. OTOVEL (ciprofloxacin and fluocinolone acetonide) otic solution Initial U.S. Approval: 2016

Approved
Approval ID

dc17b816-b97f-4c44-9f05-b41f76ab3a52

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Dec 23, 2022

Manufacturers
FDA

WraSer LLC

DUNS: 121828334

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

ciprofloxacin and fluocinolone acetonide

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code66992-128
Application NumberNDA208251
Product Classification
M
Marketing Category
C73594
G
Generic Name
ciprofloxacin and fluocinolone acetonide
Product Specifications
Route of AdministrationAURICULAR (OTIC)
Effective DateOctober 5, 2021
FDA Product Classification

INGREDIENTS (6)

GLYCERINInactive
Code: PDC6A3C0OX
Classification: IACT
POLYSORBATE 80Inactive
Code: 6OZP39ZG8H
Classification: IACT
POVIDONE K90Inactive
Code: RDH86HJV5Z
Classification: IACT
WATERInactive
Code: 059QF0KO0R
Classification: IACT
CIPROFLOXACINActive
Quantity: 0.75 mg in 0.25 mL
Code: 5E8K9I0O4U
Classification: ACTIB
FLUOCINOLONE ACETONIDEActive
Quantity: 0.0625 mg in 0.25 mL
Code: 0CD5FD6S2M
Classification: ACTIB

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

OTOVEL - FDA Drug Approval Details